Exact Sciences Corp

US

EXAS

Health Care

62.41 ₽

Current price

Sell
62.41 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    548 / 1361

  • Position in country

    8646 / 14179

  • Return on Assets, %

    -3.3

    -40.3

  • Net income margin, %

    -7.7

    -180

  • EBITDA margin, %

    -2.2

    -168.2

  • Debt to Equity, %

    75.7

    3.2

  • Intangible assets and goodwill, %

    65.7

    0.2

  • Revenue CAGR 3Y, %

    18.7

    12.5

  • Total Equity change 1Y, %

    3.3

    -9

  • Revenue Y, % chg

    19.9

    0

  • P/BV

    4.1

    1.8

  • P/S

    5.1

    10.3

  • EV/S

    5.8

    7.5

  • EV/EBITDA

    -1925.4

    -1.6

  • Average Analyst recommendation

    Buy

    Buy

  • Average upside forecasts, %

    24.2

    131.1

  • Expected dividend per share

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • Vertex Pharmaceuticals Inc

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Seagen Inc

    00%

  • Amgen Inc

    00%

  • Exact Sciences Corp

    00%

  • Moderna Inc

    00%

  • Alnylam Pharmaceuticals Inc

    00%

  • AbbVie Inc

    00%

  • Biogen Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    12950.4

  • Ticker

    EXAS.O

  • ISIN

    US30063P1057

  • IPO date

    2001-01-30

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-21

  • Date fact. publication of reports

    2023-12-31

Company Description

Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.